Clinical trials: Relapsed Leukemia
Relapsed or Refractory Acute Myeloid Leukemia
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
This is a phase 1, multi-center, single-arm study to evaluate the pharmacokinetics(PK)/ pharmacodynamics(PD), safety, and clinical efficacy of orally administered Ivosidenib in Chinese subjects with R/R AML with an IDH1 mutation.
- Trial name
- NCT04176393
- Testing
- ivosidenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- CStone Pharmaceuticals
Acute Leukemia, Myelodysplastic Syndromes
A Study of ONO-7475 in Patients With Acute Leukemias
[Updated]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes and to assess: i) safety and tolerability…
- Trial name
- NCT03176277
- Testing
- ONO-7475 3mg once daily, ONO-7475 6mg once daily, ONO-7475 10mg once daily
- Where
- 16 sites in United States
- Volunteers
- 42 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
- Trial name
- NCT07134088
- Testing
- Blinatumomab
- Where
- 5 sites in United States, Japan
- Volunteers
- 104 people
- Sponsor
- Amgen
Advanced Cancer, Solid Tumors
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
This research study is being done in people with advanced-stage solid tumor cancer. Advanced stage solid tumor cancer is a cancer that forms an abnormal mass of tissue that usually does not contain cysts or liquid areas.
- Conditions
- Advanced Cancer, Solid Tumors, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
- Trial name
- NCT03690154
- Testing
- FN-1501
- Where
- 3 sites in United States, Australia
- Volunteers
- 67 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)
Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Establishing real-world data of Chinese patients with CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) treated with Puzolcabtagene Autoleucel Injection to evaluate its effectiveness.
- Trial name
- NCT07637929
- Testing
- Puzolcabtagene Autoleucel Injection
- Volunteers
- 200 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Relapsed or Refractory Acute Lymphoblastic Leukemia
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of CNCT19 in adult patients with relapsed or refractory acute lymphoblastic leukemia.
- Trial name
- NCT04230473
- Testing
- single dose of CNCT19
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Juventas Cell Therapy Ltd.
Acute Myeloid Leukemia
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens.
- Trial name
- NCT00822094
- Testing
- CPX-351, Intensive Salvage Therapy
- Where
- 42 sites in United States, Canada and 2 more
- Volunteers
- 126 people
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukaemia (AML)
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is…
- Trial name
- NCT06788756
- Testing
- Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.
- Where
- 28 sites in United States, Czechia and 7 more
- Volunteers
- 312 people
- Sponsor
- Moleculin Biotech, Inc.
SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of relapsed and refractory CD7+ T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma
- Trial name
- NCT04916860
- Testing
- Senl-T7
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
The purpose of this study is to determine the safe dose of EPZ-5676, to evaluate the safety of EPZ-5676 in patients with advanced hematologic malignancies, and to conduct a preliminary assessment of the anti-leukemia activity of…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
- Trial name
- NCT01684150
- Testing
- EPZ-5676
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 51 people
- Sponsor
- Epizyme, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
To evaluate the safety and preliminary efficacy of acalabrutinib in combination with obinutuzumab in 4 separate cohorts of participants.
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
- Trial name
- NCT02296918
- Testing
- acalabrutinib, Obinutuzumab, Venetoclax
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Acerta Pharma BV
Cancer - Acute Myeloid Leukemia
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
An open-label, dose-escalation study to assess safety, pharmacokinetics and efficacy as well as determine the recommended Phase 2 doses of co-administered therapy of dinaciclib and venetoclax for patients with relapsed or…
- Trial name
- NCT03484520
- Testing
- Venetoclax, Dinaciclib
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 48 people
- Sponsor
- AbbVie
AML (Acute Myeloid Leukemia), BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm)
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN
This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell…
- Trial name
- NCT06690827
- Testing
- Anti-CD123 CAR NK cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or…
- Trial name
- NCT04155710
- Testing
- IOV-2001, Low dose IL-2, High dose IL-2
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Chronic Lymphocytic Leukemia
SPC2996 in Chronic Lymphocytic Leukaemia
The purpose of this study is to determine whether SPC2996 is effective and safe in the treatment of Chronic Lymphocytic Leukaemia (CLL)
- Trial name
- NCT00285103
- Testing
- SPC2996
- Where
- 12 sites in United States, Denmark and 2 more
- Volunteers
- 46 people
- Sponsor
- Santaris Pharma A/S
Acute Lymphoblastic Leukemia
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to confirm whether the bispecific T cell engager antibody blinatumomab (MT103) is effective and safe in the treatment of patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT01466179
- Testing
- Blinatumomab
- Where
- 39 sites in United States, France and 4 more
- Volunteers
- 225 people
- Sponsor
- Amgen Research (Munich) GmbH
Non Hodgkin Lymphoma
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options.
- Trial name
- NCT03779113
- Testing
- HMPL-523
- Where
- 32 sites in United States, Denmark and 5 more
- Volunteers
- 69 people
- Sponsor
- Hutchmed
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how well ABBV-453 works adult participants with relapsed/refractory (R/R) untreated CLL/small lymphocytic…
- Trial name
- 453 Ph1 CLL (NCT06291220)
- Testing
- Obinutuzumab, ABBV-453
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 4 people
- Sponsor
- AbbVie
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B cell acute lymphoblastic…
- Trial name
- NCT04404660
- Testing
- AUTO1
- Where
- 34 sites in United States, Spain and 1 more
- Volunteers
- 153 people
- Sponsor
- Autolus Limited
Leukemia
Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia
This is a Phase II trial designed to determine the efficacy and safety of perifosine in patients with leukemia who develop progressive disease or recurrence while receiving therapy.
- Trial name
- NCT00391560
- Testing
- perifosine
- Volunteers
- 19 people
- Sponsor
- AEterna Zentaris